Clinical trials database
OcuMel UK has plans to create an up-to-date clinical trials database, in memory of the late Professor Adrian Grant, former OcuMel UK volunteer and passionate advocate for clinical research. We will be working on this project with our clinical advisory panel.
Meanwhile, please see below a list of clinical trials currently open to ocular melanoma patients in the UK. This list is not exhaustive, so if you know of a trial that is not on here, please do let Jo Gumbs know on 01753 357771 or by email.
ADI-PEG 20 is an enzyme that has shown anti-cancer activity in trials with other cancers.
The trial “Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP)” (ClinicalTrials.gov Identifier:NCT02029690) is open to metastatic uveal melanoma patients.
IMCgp100 is an immunotherapy drug manufactured by Immunocore. At AACR in 2015, investigators reported responses in 2 uveal melanoma patients. You can hear more about this in Dr Pippa Corrie’s talk at our 2015 annual conference. More recently we have heard of very promising results being presented at Asco 2018.
There are two trials open in the UK. Patients need to be HLA-A2 positive, which is tested when applying to the trial. Around half of uveal melanoma patients are HLA-A2.
Phase 1 study https://clinicaltrials.gov/ct2/show/NCT02570308?term=IMCgp100&rank=5 Second line patients – this means patients who have received another form of treatment for the metastatic disease.
Phase 2 study – https://clinicaltrials.gov/ct2/show/NCT03070392?term=IMCgp100&rank=2 First line patients – this means a patient who has only received treatment to their initial primary tumour.
Liver Directed Therapy
Chemosaturation therapy (CHEMOSAT®)
Also known as Percutaneous Hepatic Perfusion (PHP), or by the brand name “Delcath”, PHP may be an option for patients with diffuse liver disease. The treatment isolates the liver from the patient’s circulatory system, and allows for the targeted administration of anti-cancer drugs at dramatically increased doses.
The treatment is given via an infusion catheter, which is inserted through the skin into the femoral artery. The blood is then cleaned before being returned to the body.
Early trials utilising this technology with uveal melanoma patients have shown promise, doubling overall survival over other targeted liver therapies – Read more here. You can find out more about the treatment on the company’s website Against The Odds.
More information on eligibility & contact information for the FOCUS trial can be found here clinical trials. Gov/ct2/show/NCT02678572
Selumetinib is a MEK inhibitor. It is being tested alongside a chemotherapy drug, paclitaxel, in the SelPac study.
The trial is due to open in 13 centres around the UK. Locations currently recruiting are: The Clatterbridge Cancer Centre, Addenbrookes Hospital, Velindre Cancer Centre, The Royal Marsden Hospital.
Patients will be randomly selected to one of three groups. One group will receive continuous selumetinib alone, one group will be given paclitaxel and continuous selumetinib, and the last group will have paclitaxel and interrupted selumetinib.
You can read more about the trial on the Cancer Research UK website.